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Alterations in neuroendocrine control of growth hormone secretion in
the uremic rat. Chronic renal insufficiency (CR1) is associated with
growth failure in children and laboratory rats and is considered to be
due, in part, to co-existent malnutrition. Alterations in hypothalamic
control of growth hormone (GH) secretion have been suggested in
uremic patients. We sought to determine whether factors unique to CR!
play a role in this disturbance of GH regulation. Using in situ hybrid-
ization histochemistry, we compared messenger RNA (mRNA) levels
for the hypothalamic neurohormones GH-releasing hormone (OHRH)
and somatostatin (SRIH) in three groups: rats with CR1 induced by 5/6
nephrectomy (NPX, N = 4); sham-operated, ad libitum fed rats (SAL,N = 5); and sham-operated, pair-fed rats (SPF, N = 5). We also
measured plasma OH at 10 minute intervals for a six hour period via
intra-atrial cannulae. The NPX group had significantly lower hypotha-
lamic GHRH mRNA concentrations than both other groups; in addi-
tion, these levels were significantly lower in the SPF than in the SAL
group. Concentrations of hypothalamic SRIH mRNA did not differ
significantly among the three experimental groups. Six-hour mean
plasma OH concentrations were significantly lower in the SPF (18.3
1.8 sg/liter) than in either the SAL (27.0 3.3 sg/1iter) or the NPX
groups (36.8 7.2 sg/liter); the difference in the mean plasma OH
levels in the NPX vs. the SAL group did not attain statistical signifi-
cance. This study provides evidence for an effect of CR1 on the
neuroendocrine control of OH secretion not related to caloric intake.
We hypothesize that a complex interplay of multiple factors leads to
altered plasma GH levels in CR1 and ultimately to growth failure. These
factors include decreased hypothalamic GHRH gene transcription and
decreased metabolic clearance of OH. We speculate that increased
circulating SRIH levels of non-hypothalamic origin and altered negative
feedback on GH secretion of both OH and insulin-like growth factor I
may also play a role in this dysregulation of plasma GH levels in uremia.
Children with chronic renal insufficiency (CR!) have failure of
linear growth which has been attributed to a number of factors:
water and electrolyte disturbances, protein-calorie deficiency,
metabolic acidosis, renal osteodystrophy, anemia, and endo-
crine disturbances, primarily of the growth hormone (OH) axis
[reviewed in 1]. With improved dietary intervention and dialysis
methodologies and the institution of alkali, calcitriol and eryth-
ropoietin therapies, many of these factors have been eradicated
to a great degree, yet growth failure remains a significant
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problem in this population of children. Although nutrition
appears to be vital in determining growth in the infant with CR1,
dietary manipulation beyond the first year of life has had little
effect on linear growth. Nevertheless, malnutrition remains an
inevitable component of CR1 [1].
One issue of contention still unresolved is the relative impor-
tance and potential interaction of malnutrition and the uremic
state itself in contributing to the alterations within the GH axis.
In rats, food deprivation has profound effects on the regulation
of GH secretion at both the hypothalamic and pituitary levels
[2—10]. CR1 may also lead to abnormalities in the GH axis
secondary to alterations in metabolic clearance [11—15] and
distribution volume [12] of the hormone. Interruption of the
normal negative feedback on GH secretion because of de-
creased end-organ responsiveness to both GH and insulin-like
growth factor I (IGF-I) has been postulated in uremia [16—20].
In humans with CR1, elevated baseline GH levels [21—24] and
abnormal (both elevated and depressed) GH secretory re-
sponses to various stimuli [25], such as hyper- and hypoglyce-
mia, arginine, GH-releasing hormone (GHRH) and L-dopa,
have been observed. However, isolated somatotropes from rats
with CR1 retain normal responsiveness to GHRH in vitro [26,
27]. Thus it appears that the hypothalamus, rather than the
pituitary gland, is a major site of dysregulation of GH secretion
in the uremic state. However, no investigations at the molecular
level into the hypothalamic control of circulating OH have been
reported in the rat to date.
We hypothesized that unique effects of CR1 on the GH axis
exist independently of those of malnutrition. We employed in
situ hybridization histochemistry to study the effects in rats of
these two physiologic stressors on the concentrations of mes-
senger RNA (mRNA) for GHRH and somatostatin (SRIH), the
two hypothalamic hormones which control pituitary GH syn-
thesis and secretion. In addition, we evaluated the effect of food
deprivation and CR1 on plasma concentration of OH, using
repeated blood sampling via intra-atrial cannulae [28]. To
undertake this study, it was decided to use the well-studied
paradigm [8, 29] of inducing CR1 in rats via 5/6 nephrectomy
[30] and then comparing these uremic animals with two sham-
operated control groups: rats fed ad libitum and those matched
for protein and caloric intake.
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Methods
Animals
Male Sprague-Dawley rats at 32 days of age and with a mean
weight of 91.8 2.0 g were obtained from Charles River
Laboratories (Wilmington, Massachusetts, USA). They were
maintained in individual cages at ambient room temperature on
12-hour light-dark cycles. Tap water was available ad libitum.
Experimental design
The experimental protocol was approved by the Institutional
Animal Care and Use Committee of the Virginia Common-
wealth University.
At 46 days of age and at a mean body weight of 192.3 4.8
g, rats underwent either 5/6 nephrectomy (NPX, N =5) or sham
surgery (N = 10) on day 0 of the study. Surgeries were
performed in two stages [30], using pentobarbital (1.25 mgIlOO g
body wt, intraperitoneally) and ketamine (4 mg/100 g body wt,
intramuscularly) anesthesia. On day 0, the left kidney was
exposed and decapsulated in all rats; the upper and lower thirds
of the organ were excised in the NPX group only. On day 7, the
right kidney was exposed and decapsulated in all rats. In the
NPX group only, the renal pedicle was ligated, and the entire
kidney was removed.
For each of the five NPX animals, one of the sham-operated
rats was chosen to be its pair-fed (SPF) control; the other five
sham-operated rats were fed ad libitum (SAL). All animals
received the same diet: standard powdered rat chow (AIN-76
Semipurified Diet, United States Biochemical, Cleveland,
Ohio, USA) modified to contain a total of 35.3% casein; protein
supplementation was provided to exacerbate the uremic state of
the NPX animals and to ensure a normal protein intake in the
SPF animals.
Intra-atrial cannulae were placed under ether anesthesia in all
rats on day 17, and repetitive plasma sampling for GH using 0.2
ml aliquots (with replacement of the red blood cells after
resuspension in normal saline) was undertaken at 10 minute
intervals for a period of six hours (from 1030 to 1630 hr) on day
21 [28]. One of the NPX animals died shortly after this proce-
dure and was excluded from the study (N = 4).
All animals were sacrificed by decapitation on day 22. The
brains were removed immediately, frozen on dry ice and then
stored in aluminum foil and plastic wrap at —80°C until further
use. For histological sectioning, the brains were allowed to
equilibrate in a cryostat at —16°C. Coronal sections were made
at 16 tm and then thaw-mounted on gelatin-coated slides.
Using a standard rat brain atlas [311, sections were obtained
between plates 22 and 25 inclusive (hypothalamic periventricu-
lar nuclei) for SRIH and between plates 29 and 33 inclusive for
GHRH (hypothalamic arcuate and ventromedial nuclei). Tissue
sections were stored at —20°C until processing for in situ
hybridization.
In situ hybridization histochemistry
The following DNA oligoprobes were constructed: a 45-base
construct complementary to nucleotides 31-75 of rat pre-
proGHRH mRNA [32] and a 30mer complementary to nude-
otides 310-339 of rat preproSRlH mRNA [33]. Oligoprobes
were separately 3'-end-labeled [34] with [35S]-deoxyadenosine
5'-[a-thio]-triphosphate (NEN Research Products, DuPont
Company, Boston, Massachusetts, USA) and terminal deoxy-
nucleotidyl transferase (IBI, New Haven, Connecticut, USA)
to final specific activities of approximately 1 X i09 dpmig.
For each probe, all brain sections (approximately 20 per
animal) were processed in a single batch to prevent interassay
variability. The methodology for the in situ hybridization has
been described elsewhere [35]. The amount of radiolabel added
to each slide of four tissue sections was approximately 1 x 106
dpm for GHRH and 3 x 106 dpm for SRIH. The final washes
were in 0.5x SSC for one hour at 45°C for GHRH and at 40°C
for SRIH. The slides were then exposed to X-ray films, and the
latter were developed after 21 days for GHRH and after three
days for SRIH.
Densitometric analysis was performed at the Biomedical
Image Processing Center of the University of Virginia. The
system used consists of a Leitz Orthoplan microscope, a Dage
Model 68 Newvicon video camera with external gain and black
level control, and a Gould 1P8500 image processing system
which are driven by customized image analysis software [36].
All densitometric analyses were performed in a blinded manner
by one observer (D.L.M.). Results of densitometry are ex-
pressed as the absolute area of signal (in m2), the optical
density of the image compared to background (in relative OD
units), and the product of these two [referred to here as the OD
index, expressed as (pm2 x OD units)].
Immunoassay
GH was measured using a radioimmunoassay described
previously [37]. The lower limit of detection of this assay was
4.0 .tgIliter. The intra-assay coefficient of variation was 10.5%.
The GH results from one SPF animal were uninterpretable
because of technical error.
Data analysis
Results are reported as mean SEM. The normality of all data
sets was assessed by the application of the Wilk-Shapiro
statistic; logarithmic transformation was undertaken prior to
analysis for all data sets not normally distributed. A priori
comparisons of data between the SAL rats and either the SPF
or the NPX rats were made using the two-tailed, unpaired
Student's t-test. Comparisons of results between the SPF and
the NPX rats were made with the two-tailed, paired Student's
1-test. A value of P < 0.05 was accepted as statistically
significant.
Results
Table 1 shows the results of treatment on weight gain, food
consumption and food efficiency (defined as g of body weight
gained per g of food consumed) in the three experimental
groups from day 8 to day 22. Both weight gain and food
efficiency were greatest in the SAL group, intermediate in the
SPF group and lowest in the NPX group, with significant
differences noted among all three groups. In addition, food
consumption was significantly greater in the SAL group than in
either the SPF or the NPX group.
Localization of quantifiable mRNA for both GHRH and
SRIH was observed in the appropriate hypothalamic nuclei of
all animals (Fig. 1). Because the reticular pattern of signal for
GHRH in the ventromedial nuclei precluded accurate densito-
metric analysis, only the arcuate nuclei were evaluated for
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Table 1. Comparison (mean SEM) of the effects of treatment on
weight gain, food consumption and food efficiency from day 8 to day
22 in 5/6 nephrectomized (NPX), sham-operated, ad libitum fed
(SAL) and sham-operated, pair-fed (SPF) rats
SAL SPF NPX
(N=5) (N=5) (N=4)
Weight gain 6.0 0.3 2.8 0.5' —1.4 0.8c
giday
Food consumed 27.7 l.9 18.5 1,2" 17.8 2.0"
giday
Food efficiency" 0.22 o.ola 0.15 0,02b —0.09 0.05c
d Food efficiency is defined as g of body weight gained per g of food
consumed. Within a row, differences in data not sharing identical
superscripts are statistically significant (P < 0.05).
GHRH mRNA content. Since we had previously observed that
the rostral portion of the periventricular nucleus corresponding
to plates 24 and 25 of the reference rat brain atlas [31] has the
highest content of SRIH mRNA (unpublished results), the data
from this segment were also analyzed separately.
In Table 2 are shown the results of densitometric analysis of
hypothalamic GHRH gene transcript levels. The mean area of
the GHRH mRNA signal was significantly decreased in the
NPX versus the SAL group (P = 0.01), in the NPX versus the
SPF group (P = 0.0002), and in the SPF versus the SAL group(P = 0.04). The mean optical density was significantly lower in
the NPX versus the SAL group (P = 0.006). Finally, the mean
OD index of the GHRH mRNA signal was significantly de-
creased in the NPX versus the SAL group (P = 0.005), in the
NPX versus the SPF group (P = 0.04), and in the SPF versus
the SAL group (P < 0.05).
Table 3 lists the results of quantitation of SRIH mRNA
levels. Although the mean SRIH mRNA abundance by all
measures was highest in the SAL group, intermediate in the
NPX group and lowest in the SPF group, these results did not
attain statistical significance in the number of rats studied. The
only difference noted among the three groups was a significantly
larger mean area of SRIH mRNA signal in the NPX versus the
SPF group (P = 0.03) in the subsegment of the periventricular
nuclei corresponding to reference plates 24 and 25.
In Table 4 are shown the results of the six-hour mean plasma
GH concentrations for the three groups of experimental ani-
mals. Mean GH levels were significantly higher in the SAL
versus the SPF group (P < 0.05), and they were also greater in
the NPX versus the SPF group (P = 0.03). Although the mean
GH concentrations were higher in the NPX versus the SAL
group, this difference did not attain statistical significance. Also
shown are the recently reported [15] GH plasma elimination
half-lives for these animals, as determined by deconvolution
analysis [11] of plasma GH concentration-versus-time series.
The half-life is significantly greater in the NPX versus both the
SAL (P = 0.002) and the SPF (P = 0.02) groups; it is also
significantly greater in the SPF versus the SAL group (P
0.01).
Discussion
In this study, we hypothesized that both malnutrition and
CR1-specific factors can alter the physiology of GH secretion in
the uremic rat. Using in Situ hybridization histochemistry, we
have demonstrated significant reductions in gene expression of
GHRH, one of the major hypothalamic neuroregulators of GH
release, in food-deprived and uremic rats. Associated with
these changes was a marked decrease in six-hour mean plasma
GH concentrations in the malnourished (pair-fed) rats com-
pared to both the ad libitum fed and the uremic rats. Given the
alterations in hypothalamic GHRH mRNA content—which are
significantly more pronounced in CR1 than in simple food
deprivation—and the divergent plasma GH levels among the
three groups, we contend that factors in uremia other than
decreased caloric intake are involved in the etiology of these
observed changes.
The experimental model used here, 5/6 nephrectomy, pro-
duces a state of mild to moderate renal failure with elevated
plasma urea nitrogen and creatinine levels [8, 23, 26, 27, 29, 30].
Nephrectomized animals also exhibit markedly decreased ca-
loric intake and food efficiency, which result in poor weight gain
and decreased linear growth [8, 23, 26, 27]. Sham-operated,
pair-fed animals generally demonstrate weight gain, linear
growth and food efficiency intermediate between nephrecto-
mized and ad libitum fed controls [8, 23]. The results presented
in Table 1 are therefore compatible with previous findings.
Food deprivation has profound effects on the GH axis of the
rat. Our finding of significantly decreased plasma GH concen-
trations in the SPF versus the SAL rats confirms previous
observations in the food-deprived rat [2, 4—7]. Moreover, the
deconvolution-derived GH elimination half-life is significantly
longer in the SPF versus the SAL rats [15]; other researchers
have also documented that fasting in rats is associated with a
decrease in both the metabolic clearance rate and the apparent
distribution volume of GH [38]. It is therefore likely that the
lower plasma GH levels observed in the food-deprived (SPF)
rats specifically reflect decreased pituitary GH secretion. The
cause of this diminution in GH production is not known with
certainty. Using an early bioassay, Meites and Fiel [3] demon-
strated that the hypothalami of starved rats contain less GHRH-
like activity than controls fed ad libitum. This is corroborated
by our observation that the SPF animals have significantly
lower hypothalamic GHRH mRNA content than the SAL
group. Similar findings of decreased GHRH mRNA levels—but
with normal GHRH peptide content—in the hypothalami of
starved rats have also been observed by Bruno et al [9]; this
appears to a specific effect of protein deprivation [10]. It should
be mentioned that these findings in rats are in sharp contradis-
tinction to those in humans, in whom fasting is associated with
large increases in GH secretion [39].
Increased SRIH tone also appears to play a role in the
decreased plasma GH levels of starvation. Endogenous and
exogenous SRIH have inhibitory effects on both hypothalamic
GHRH release and pituitary GH secretion [40]. Indeed, func-
tional SRIH receptors have been identified on GHRH-secreting
neurons in the hypothalamic arcuate nucleus [41]. Tannenbaum
and colleagues [2] showed that passive immunization with
antiserum to SRIH restores normal pulsatile GH secretion in
malnourished rats. While it is agreed that fasted rats have
increased circulating plasma concentrations of SRIH similar to
normal peak concentrations in hypothalamic portal blood [6],
the source of this SRIH is disputed. Mounier and coworkers [7]
demonstrated that mean GH levels do not decrease further with
starvation in rats which have undergone hypothalamic-pituitary
disconnection, indicating that the increased SRIH of starvation
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Fig. 1. Autoradiographs on X-ray film from in situ hybridizationfor GJJRH and SRI!! mRNA in the hypothalamus of a control rat. There is dense
localization of OHRH mRNA in the arcuate nuclei (A). Note also the fainter, reticular pattern of signal in the ventromedial nuclei. B. Demonstrates
the dense localization of SRIH iriRNA in the periventricular nuclei of the hypothalamus; there is also diffuse signal throughout the cerebral cortex
consistent with the role of SRII-l as a prevalent neurotransmitter.
Table 2. GHRH mRNA content (mean saM) in the hypothalamic




Area(x l0—) jun2 15.7 1.6" 11.3 08" 9.0 0.7"
Optical density 0.42 0.03k 035 004"." 0.28 0.02"
relative 00 units
GD index (x l0—) 67-2 10.4" 39.9 6.1" 25.3 t 4.0"
— X OD units
Within a row, differences in data not sharing identical superscripts
are statistically significant (P <0.05). See Table 1 for abbreviations.
Table 3. SRIH mRNA content (mean saM) in the hypothalamic
periventricular nuclei of the experimental animals
SAL SPF NPX
Platese (N=5) (N = 5) (N = 4)
Area (x l0—) 22—25 28.0 5.1 19.2 2.5 24.4 3.4
jun2 24—25 41.4 12.0"-" 31.0 1.7" 39.6 3,3"
Optical density 22—25 0.49 0.04 0.43 0.02 0.43 0.02
relative OD 24—25 0.54 0.03 0.51 0.18 0.49 0.04
units
GD index (x 10—s) 22—25 154.6 37.9 89.1 13.6 118.7 23.4
jun2 x GD units 24—25 235.2 37.7 160.7 4.7 202.1 31.1
a,b Within a row, differences in data not sharing identical superscripts
a and b are statistically significant (P < 0.05). See Table 1 for
abbreviations.
Plates 22—25 represent the entire segment of the periventricular
nuclei studied; plates 24—25 represent the subsegment of these nuclei
with the greatest SlUM mRNA content.
is of central origin. Other investigators, however, have ob-
served increased levels of SRIH peptide in the pancreas and
gut—but not in the hypothalamus—of food-deprived rats [5].
indeed, there is a significant increase of SRIH mRNA content
in rat gastric antrum within 12 hours of the onset of fasting [42].
Bruno and coworkers [91 likewise found unchanged SRIH
mRNA and peptide concentrations in the hypothalami of
starved rats versus fed controls. In our study, the hypothalamic
content of SRIH inRNA is statistically indistinguishable in the
SAL and the SPF animals. We are therefore unable to provide
Table 4. Six-hour mean (± 5EM) plasma OH concentrations and
plasma GH elimination half-lives in the experimental animals
SAL(N=5) SPE(N=4) NPX(N=4)
Six-hour mean plasma 27.0 3.3" 18.3 1.8" 36.8 7.2"
OH g/liler
Plasma half-life mitt 11.5 0.6" 13.9 o.t 16.5 0.8
Elimination half-lives were determined by deconvolution analysis
and previously reported in reference 15. Within a row, differences in
data not sharing identical superscripts are statistically significant (P <
0.05). See Table 1 for abbreviations.
further evidence for the origin of the increased SR1H tone in
starvation.
CR1 also exerts a number of effects on the OH axis [14].
Studies in humans have shown that random and serial OH
concentrations are generally increased in CR1 [21, 22, 241.
Likewise, one previous study has demonstrated higher random
OH concentrations in uremic rats compared to both ad libiturn
and pair-fed controls [23]. However, while Lacour and col-
leagues did not observe any differences in random serum OH
concentrations between similar groups, they did demonstrate
significantly higher pituitary (3M content in uremic rats than in
control rats fed ad libitum [29]. This latter phenomenon is
consistent with the finding of increased SRIH tone in CR! [43].
This study represents the only investigation to date using
repeated blood sampling for OH in uremic rats. While our data
suggest that mean plasma OH concentrations may be elevated
in the uremic (NPX) versus the SAL group, this difference did
not attain statistical significance in our limited number of
animals. Nonetheless, mean plasma OH levels are significantly
higher in the NPX than in the SPF group; this suggests that
there may be two opposing influences on OH concentrations in
rats with CR1: starvation, which is inhibitory to OH production,
and some factor(s) unique to uremia which is causing an
apparent elevation in plasma OH concentrations. Additionally,
it is unknown whether some partially degraded, bioinactive
forms of OH could interfere with the R!A and result in
spuriously high immunoactive OH levels [14, 38].
Either a decrease in metabolic clearance or an increase in
- *.. - * *
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pituitary GH secretion, or both, could lead to increased circu-
lating OH in rats with CR1. Plasma GH elimination half-life is
significantly greater in the NPX versus either the SPF or the
SAL group [15]; similar findings have also been demonstrated in
humans [12, 14, 24]. Since up to 70% of circulating OH may be
degraded in the rat kidney [13], this increased elimination
half-life may reflect a reduction of glomerular clearance of OH
in CR1. GH is also eliminated from the plasma through its
binding to GH receptors on target tissues with subsequent
hormone-receptor complex internalization and lysosomal deg-
radation [44]. A decrease in the number of hepatic OH-binding
sites, such as is observed in uremic rats [16], could therefore
lead to reduced clearance of GH. A decrease in GH-binding
protein, such as has been documented in uremic children [17],
or an alteration in its binding equilibrium with GH could also
potentially affect hormone clearance [14]. Finally, the volume
of distribution of growth hormone is significantly increased in
human with CR1 [12]; any estimate of endogenous GH produc-
tion or clearance must necessarily take this fact into consider-
ation.
Direct measurements of OH production rates were not per-
formed in this study; these await the application of newer
mathematical techniques, such as deconvolution modeling [11],
to a larger number of plasma OH concentration-versus-time
series from uremic humans and rats. Nonetheless, the finding of
significantly lower hypothalamic levels of GHRH mRNA in the
NPX versus the SAL rats offers indirect evidence that GH
production may be severely diminished in CR1. Furthermore,
because these values are even lower in the NPX versus the SPF
rats, this decrease in hypothalamic GHRH mRNA content
associated with CR1 cannot be ascribed to caloric deprivation
alone. Since the hypothalamic content of SRIH mRNA was not
significantly different between the NPX and the SPF group, we
are unable to explain the higher GH concentrations in the NPX
group on the basis of altered hypothalamic SRIH input. Nev-
ertheless, plasma SRIH peptide concentrations are increased in
adults with CR1 [43]. The reason for this is uncertain, but it does
not appear to be a result of impaired metabolic clearance of
SRIH [43]. It is also unknown whether plasma SRIH levels are
higher in uremic rats versus pair-fed controls, that is, whether
malnutrition is the sole reason for the elevated SRIH. Future
studies will need to elucidate the relative contributory roles of
decreased GH clearance and neuroendocrine dysregulation of
OH secretion to the observed alterations of plasma GH levels.
At present, it is not known which factor(s) peculiar to uremia
might explain the non-caloric intake-related alterations in hy-
pothalamic control of GH secretion. In healthy humans and
rats, both OH and IGF-I exert negative feedback inhibition on
OH production; this is mediated at least in part through SRIH
[40]. A state of primary resistance to GH is postulated to occur
in CR1, since uremic rats have fewer hepatic OH-binding sites
than controls [16], and children with CR1 have decreased
plasma concentrations of OH-binding protein, an indirect mea-
sure of GH receptor number [17]. However, the significance of
these alterations on hormone end-organ action have not been
completely elucidated. Notwithstanding any resistance to OH,
the product of its action on target tissues, IGF-I, is found in
normal concentrations by immunoassay in the plasma of chil-
dren [18] and rats [8] with CR!. However, the bioactivity of
IGF-I is reduced, probably because of the accumulation in
Fig. 2. Hypothetical model of the effects in the rat of caloric depriva-
tion and CR1 on GH secretion and elimination as manifested by
alterations in peripheral OH concentrations. In malnutrition (left), GH
production is decreased secondary to diminished hypothalamic GHRH
synthesis and to increased SRIH tone, probably of non-hypothalamic
origin. Despite a small increase in plasma elimination half-life, periph-
eral levels of OH are decreased in malnutrition. In CR1 (right),
hypothalamic GHRH levels are lower still, leading to decreased OH
production; in addition, plasma OH half-life is markedly prolonged in
CR!. The effects of co-existent malnutrition and CR1-specific factors
lead to an overall increase in plasma OH levels in the uremic rat.
uremia of IGF-binding proteins [18, 20], which act to maintain
free IOF-I at very reduced concentrations. In addition, other
researchers have identified a low molecular weight (<1 kD),
non-protein, dialyzable inhibitor of IGF-I-induced sulfate and
uridine uptake into cartilage [19]. If this end-organ resistance to
GH and/or IGF-I extended to the hypothalamic-pituitary-OH
axis, GHRH gene transcription might be expected to increase to
provide a compensatory rise in OH secretion. Since this was
not observed in our experiment, other unidentified factors may
be involved which inhibit GHRH gene expression.
In summary, our preliminary study in a limited number of
animals has demonstrated that the neuroendocrine regulation of
GH secretion is altered at the hypothalamic level in rats with
CR1 (Fig. 2). We observed that uremic rats have decreased
hypothalamic concentrations of mRNA for GHRH, even when
compared to pair-fed controls. This provides evidence for an
effect of uremia on hypothalamic OHRH gene expression that is
not related to caloric intake. We were unable to demonstrate
alterations in SRIH mRNA content in the hypothalamus caused
by either food deprivation or CR1. Despite the decreased
OHRH mRNA content and the unchanged SRIH mRNA con-
tent in the hypothalamus, plasma GH levels are increased in
CR!. We speculate that other factors are involved which may
alter GH concentrations in CR1. These could include decreased
renal (and perhaps extrarenal) clearance and increased distri-
bution volume of the hormone, increased SRIH tone of non-
hypothalamic origin, as well as alterations of GH and IGF-I
negative feedback on the neuroendocrine regulation of OH
secretion.
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